HeartCoffee
Well-known member
https://www.science.org/content/blog-post/novo-nordisk-s-canadian-mistake
Great summary on a tech site:
Pharmaceutical giant messed up patent protection for semaglutide in Canada by not paying a small maintenance fee in 2019. They'd been paying, then asked for a refund for 2017, and just never paid the 2019 fee. Canada's a big market for these drugs. A generic company may be able to launch a version in 2026, while the U.S. patent lasts longer.
Great summary on a tech site:
Pharmaceutical giant messed up patent protection for semaglutide in Canada by not paying a small maintenance fee in 2019. They'd been paying, then asked for a refund for 2017, and just never paid the 2019 fee. Canada's a big market for these drugs. A generic company may be able to launch a version in 2026, while the U.S. patent lasts longer.